< Back to previous page
Researcher
Els Dequeker
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Biomedical Quality Assurance Research Unit (Division)
Responsible
From1 Jan 2012 → Today - Biomedical Quality Assurance Research Unit (Division)
Member
From1 Jan 2012 → Today - Department of Human Genetics (Department)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 10
- The changing HER2 biomarker testing policy: Impact and training for the Belgian pathology laboratoriesFrom12 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Quality improvement of diagnostic processes in the oncology fieldFrom18 Oct 2021 → 15 Jan 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Evaluation of Scientific Publications to Predict the to be Expected Research Quality in Collaborations with External Service ProvidersFrom1 Oct 2021 → TodayFunding: Baekeland
- Quality improvement in molecular pathology laboratories: providing the means for process management and standardization of pre-analytical handling of small biopsies.From22 Apr 2021 → 8 Jan 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Organize distance laerning in the form of External Quality Assessment schemes.From1 Oct 2018 → 30 Sep 2019Funding: Private funding of national origin - undefined
- Early prediction/detection of clinical response in metastatic NSCLC by improving liquid biopsy analysisFrom4 Sep 2017 → 1 Jan 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Quality in Molecular Oncology Testing Laboratories in Europe: a View from Different AnglesFrom18 Jul 2016 → 22 Dec 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Quality improvement tools for predictive testing in pathologyFrom11 Sep 2015 → 28 Aug 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Future of Personalised Medicine: Quality Assurance of Oncology Biomarker Testing is EssentialFrom1 Aug 2013 → 21 Jan 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- EuroGentest2: Genetic testing in Europe - Network for the further development, harmonization, validation and standardization of services.From1 Jan 2011 → 31 Dec 2013Funding: General Activities (Annex IV)
Publications
31 - 40 of 94
- Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples(2020)
Authors: Cleo Keppens, Els Dequeker, Kelly Dufraing
Pages: 366 - 377 - Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients(2020)
Authors: Kelly Dufraing, Cleo Keppens, Sara Vander Borght, Els Dequeker
- External quality assessment for molecular diagnostic laboratories in Belgium: Can we improve it?(2020)
Authors: Kelly Dufraing, Els Dequeker
Pages: 39 - 49 - Two years of BRCA1 and BRCA2 somatic external quality assessment with Gen&Tiss scheme in France(2019)
Authors: Kelly Dufraing, Céline Garrec, Caroline Egele, Cleo Keppens, Jean Chiesa, Aude Lamy, Ludovic Lacroix, Alexandre Harlé, R Pascal, Kaat Van Casteren, et al.
- Variation in nomenclature of somatic variants for selection of oncological therapies: can we reach a consensus soon?(2019)
Authors: Cleo Keppens, Véronique Tack, Kelly Dufraing, Els Dequeker
Pages: 7 - 16 - Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study(2019)
Authors: Kelly Dufraing, Gert De Hertogh, Els Dequeker
Pages: 312 - 319 - Pre-Analytical Challenges during RAS Testing: Tissue Quality and the Estimation of Neoplastic Cell Percentage(2019)
Authors: Kelly Dufraing, Cleo Keppens, Bert Siebers, George Kafatos, Kimberly Lowe, Gaston Demonty, Els Dequeker, Han van Krieken
Pages: 1 - 1 - IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.(2019)
Authors: Els Dequeker, Cleo Keppens
Pages: 681 - 689 - European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects(2019)
Authors: Cleo Keppens, Kelly Dufraing, Els Dequeker
Pages: 25 - 37 - Future of Personalised Medicine: Quality Assurance of Oncology Biomarker Testing is Essential(2019)
Authors: Véronique Tack, Els Dequeker